Novartis at ESMO

Novartis 2020 ESMO Annual Meeting Virtual Portal

Novartis at ESMO image

We are boldly reimagining cancer and blood disorders.

…

/by

Novartis Tafinlar® + Mekinist® demonstrates long-term, relapse-free survival benefit for high-risk, stage III melanoma patients in study published in NEJM

 

  • COMBI-AD is first trial to demonstrate 5-year relapse-free survival with targeted therapy as adjuvant treatment in high-risk patients with stage III BRAF-mutated melanoma1
     
  • Adjuvant treatment with standard-of-care targeted therapy Tafinlar + Mekinist reduced the risk of relapse or death by 49% compared to placebo1
     
  • Updated data show Tafinlar + Mekinist improved distant metastasis-free survival, a secondary endpoint1

             
Basel, September 16 …

/by

Committed to increasing access

Patient and healthcare worker in Vietnam

Novartis reinforces its commitment to environmental, social and governance (ESG) principles and the …

/by

Novartis reinforces commitment to patient access, pricing a EUR 1.85 billion sustainability-linked bond

  • First healthcare industry sustainability-linked bond (SLB) further embeds Environmental Social Governance (ESG) targets into the core of Novartis business operations

  • SLB linked to 2025 Patient Access Targets to increase patients reached in low- and middle-income countries (LMICs) with strategic innovative therapies by 200% and the Novartis Flagship Programs by 50%

Basel, September 16, 2020 — Novartis today announced the pricing of a EUR 1.85 billion sustainability-linked bond (SLB), reinforcing its commitment to ESG …

/by

Bringing science and medicine together to help patients with cancer

One of the biggest game-changing advancements in cancer care came about 20 years ago when researchers learned that they could create medicines that selectively jam up cancer’s growth machinery without damaging the rest of the body. Today these medicines, called targeted therapies, are available for treating many forms of cancer.

Targeted therapies took center stage when Alice Shaw started her career as a physician-scientist caring for patients with lung cancer. Now, as Global Head of Translational Clinical Oncology at the Novartis Institutes for BioMedical Research (NIBR), Shaw aims …

/by

European Medicines Agency (EMA) approves safety label update for Novartis Beovu®

  • Novartis worked with the EMA to update the Beovu® (brolucizumab) label to guide physicians in their treatment of wet AMD  
     
  • The update includes the additional characterization of retinal vasculitis and/or retinal vascular occlusion, typically in the presence of intraocular inflammation1
     
  • Novartis has established a multidisciplinary panel of internal experts collaborating with external advisors to examine the root cause, potential risk factors and mitigation of these adverse events
     
  • …
/by

Novartis reports positive topline results from the first Phase III trial of Beovu® versus aflibercept in patients with diabetic macular edema (DME)

  • In Phase III KITE study, Beovu (brolucizumab) 6 mg achieved its primary endpoint of non-inferiority to aflibercept 2 mg in mean change in best-corrected visual acuity (BCVA) at year one (week 52)1
     
  • In a key secondary endpoint, more than half of Beovu patients were maintained on a three-month dosing interval through year one, following the loading phase1
     
  • Beovu showed superior improvement versus aflibercept in change of central subfield thickness, a secondary endpoint, over the period of week 40 through week 521 …
/by

Novartis data show early treatment with Mayzent® (siponimod) delays disability progression and show benefits in cognitive performance in patients with secondary progressive multiple sclerosis (SPMS)

  • Post hoc EXPAND analysis showed improvements in cognitive processing speed in patients with active and non-active SPMS treated with Mayzent1
     
  • Subgroup analyses of the EXPAND trial showed the value of early treatment initiation with Mayzent in patients with active SPMS as positive effects on disability, cognitive processing speed and relapse outcomes were sustained for up to five years2
     
  • Results from EXCHANGE interim analysis presented at ACTRIMS-ECTRIMS reinforced its safety and tolerability …
/by

Novartis presents data at ACTRIMS-ECTRIMS for Kesimpta® (ofatumumab) in newly diagnosed treatment-naïve adults with relapsing multiple sclerosis

  • New post hoc data from Phase III ASCLEPIOS trials showed newly diagnosed, treatment-naïve patients experienced reductions in annualized relapse rates, MRI lesion activity and reductions in time to disability worsening when treated with Kesimpta vs teriflunomide1
  • Additional safety data in over 1,800 patients who continued Kesimpta treatment or switched therapy from previous studies reinforce the favorable safety profile of Kesimpta in patients with relapsing forms of multiple sclerosis (RMS)2
     
  • Baseline serum …
/by

Not your grandparents’ nuclear medicine

In the late 1800s, at a time when people still traveled in horse-drawn carriages and lit homes with wax candles, scientists discovered nuclear power. They found curious elements, such as uranium and radium, which emit invisible rays of energy. They called this energy radiation. 

When they noticed that radiation had the power to burn skin, they applied it to treat cancer. The benefits were evident, but it would take scientists decades to understand how to wield the energy that emerges from the core of these special atoms safely.

Now, a new form of nuclear medicine is on the …

/by